Dave. you, Thank
in presence is the there normal around tissue as or the PD-X compared both tumor and higher and microenvironment, area to tumor tumor expression the VEGF Importantly, potentially body. tissue of the in
of attaching the system and killing these The molecule T-cell single tetravalent bringing in binding design novel therapy cooperative healthy by T-cell cells the a direct the a have targets into ivonescimab tumor a intentional prevent first tissue. place. the that versus port bispecific the the potential qualities the to tumor job tissue in actually from of structure, the X doing antibody assists with to immune Anti-PD-X to
system built-in checkpoint a prevent cancer take that tumor intended immune the cells of overreacting. to the is advantage Some on T-cell from
on sequential checkpoint and to the we PD-X T-cell the to the blood helps administration a VEGF ivonescimab anti-PD-X better allowing to immune a helps the do just hence, an VEGF anti-VEGF allows checkpoint blood of to fight referred to goes system or cells mechanisms, bind binding build break; of than also as nutrition tumor can deplete it's supply new Anti- T-cell, binding and this its tumor. the cooperative further through to tumor. therapy inhibitor. the Anti-VEGF by the blood to therapy VEGF. job Anti-PD-X without therapy believe described. We
its in is ability to is just improve to was on stronger such side sum addition safety established greater associated than effects design the The standards the designed profiles of X novel intent with is up in the and efficacy that this Ivonescimab targets. these compound parts. previously
program Our the is plans clinical Non-small development cell first step. expand to place. cancer to remain in continue our lung only
both development confidence in to lung cycle. other expand cancer tumors indications cell in solid to during in ivonescimab and have its additional continue We non-small life in
Akeso with this mindset. with agreement Our drawn was up
strongly We ivonescimab. of the in potential believe
requests with of leaders. key IST related well We can to for as message investigator-sponsored as physician to in our other as appreciate and of continue their cancer. enthusiasts ivonescimab level leaders have for high lung trials, do opinion broaden We begun we programs, ivonescimab accepting outside what the
inquiries additional to information programs we potential have we We related in multiple and IST to considering, that received expect XXXX. are share
Finally, say our about like to word team. I a would
to Based complete of and members Fong, team. able Team Dave, outstanding Allen accomplishments leadership have congratulate we have on Urte, to years, in excited the couple well-deserved the over us months. Jack certain They last present roles. as most therapies of development substantial some cancer new Chow of significant oncologists attract years and experience our clinical that we cancer time. I very our have past in team. physicians their been also of Summit Dr. development I'm well practicing management medical as experience treatment the the the XX Dr. combined of over of each Laura West in joined have over now represent as elevated
in each trailblazer anti-angiogenic a place, is lung Laura renowned Summit dedication and I expert in mission as focused as cancer is Jack Dr. a primarily a is novel lung like West goals. member truly immunotherapies well to team Team and thank the for amazing and and our cancer their would our special cancer. to of Dr. Chow head and neck treatment
I our on and ask to financial details will Ankur? additional provide position Now Ankur outlook.
